rolafagrel has been researched along with thromboxanes in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benigni, A; Bertani, T; Corna, D; Gabanelli, M; Morigi, M; Perico, N; Remuzzi, G; Zoja, C | 1 |
Bartoli, A; Bertin, D; Gatti, G; Perucca, E; Strolin-Benedetti, M | 1 |
Dho, L; Patrono, C; Rimoldi, O; Salvati, P; Ukmar, G; Vaga, L | 1 |
3 other study(ies) available for rolafagrel and thromboxanes
Article | Year |
---|---|
Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Bleeding Time; Blood Pressure; Epoprostenol; Imidazoles; Kidney; Kidney Diseases; Male; Naphthalenes; Platelet Aggregation; Proteinuria; Rats; Rats, Inbred Strains; Thromboxane B2; Thromboxane-A Synthase; Thromboxanes | 1990 |
Pharmacokinetic and pharmacodynamic studies following single and multiple doses of rolafagrel, a novel inhibitor of thromboxane synthase, in normal volunteers.
Topics: Administration, Oral; Adult; Blood Platelets; Drug Administration Schedule; Humans; Imidazoles; Intestinal Absorption; Male; Naphthalenes; Thromboxane-A Synthase; Thromboxanes | 1994 |
A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
Topics: Animals; Carbazoles; Carotid Artery Thrombosis; Copper; Coronary Thrombosis; Disease Models, Animal; Dogs; Evaluation Studies as Topic; Imidazoles; Male; Naphthalenes; Platelet Aggregation; Prostaglandin H2; Prostaglandins H; Rabbits; Receptors, Prostaglandin; Receptors, Thromboxane; Receptors, Thromboxane A2, Prostaglandin H2; Thromboxane B2; Thromboxane-A Synthase; Thromboxanes | 1994 |